AB0198 EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB BIOSIMILAR: 100 MG/ML) IN COMPARISON WITH THE MAINTAINED TREATMENT (CT-P17 OR REFERENCE ADALIMUMAB) IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULT

D. Furst, E. Keystone,J. Kay, J. Jaworski, R. Wojciechowski,P. Wiland, A. Dudek, M. Krogulec, S. Jeka,A. Zielinska, J. Trefler, K. Bartnicka-Masłowska, M. Krajewska-Wlodarczyk, P. Klimiuk, S. J. Lee,S. H. Kim,Y. Bae, G. Yang, J. Yoo,T. Kim

Annals of the Rheumatic Diseases（2021）

引用 1|浏览6

暂无评分

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要